NovaBridge Biosciences (NBP) Form 6-K — Oct 23, 2026

$NBPForm 6-KFiled Oct 23, 2026, 9:15 AM ET0001193125-26-429548Original filing

NovaBridge Biosciences announced in a 6-K that clinical data from the ongoing Phase 1 trial of ragistomig (ABL503/TJ-L14B), a PD-L1 x 4-1BB bispecific antibody, was presented in a poster at the ESMO Congress 2026 in Madrid on October 23, 2026. The asset is being jointly developed with ABL Bio Inc., which delivered the presentation.

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.